May 10, 2017
Biocartis welcomes new CEO
Biocartis Group has appointed Herman Verrelst as its new Chief Executive Officer (CEO), effective as of August 2017.
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
May 9, 2017
J&J discloses U.S. probe related to arthritis drug
Healthcare conglomerate Johnson & Johnson <JNJ.N> said on Monday the U.S. Justice Department has opened an investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that bought two of its drugs.
May 9, 2017
Portola Pharmaceuticals reports loss of $41.7M
Portola Pharmaceuticals has reported financial results for the quarter ended March 31, 2017.
May 8, 2017
Teva’s and Active Biotech’s multiple sclerosis drug fails meeting primary endpoint
Teva Pharmaceutical Industries and Active Biotech have reported that the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS) did not meet its primary endpoint.
May 8, 2017
Ipsen buys five Sanofi’s products
Ipsen has completed acquisition of a portfolio of five consumer healthcare products from Sanofi.
May 8, 2017
IDMC gives green light for extension of Faron Pharmaceuticals’s rare lung disease
Faron Pharmaceuticals has received the Independent Data Monitoring Committee’s (IDMC) recommendation to continue the INTEREST Phase III study for the treatment of patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) with its lead product Traumakine.
May 8, 2017
MT Pharma America accepts ALS challenge – wins FDA approval
Its have been three years since Ice bucket challenge went viral promoting awareness of amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease and encourage donations to research.
May 5, 2017
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
MDxHealth has signed an agreement with the Faculty of Health, Medicine and Life Sciences / School for Oncology and Developmental Biology (GROW) at Maastricht University to expand its existing research collaboration to develop commercial next generation (epi)genetic cancer diagnostics.
May 5, 2017
Genfit enrolls first patients in its liver disease drug test
Genfit, a biopharmaceutical company focused on developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, has started patient testing in the Phase 2a trial evaluating elafibranor in PBC.
May 5, 2017
Tetraphase Pharmaceutical reports $29.5M for Q1 2017
Tetraphase Pharmaceutical has reported a net loss of $29.5 million for the first quarter of 2017 which is decrease compared to a net loss of $16.7 million for the same period in 2016.